Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
TAP1 Double Nickase Plasmid (h): sc-405210-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- TAP1 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- TAP1 Double Nickase Plasmid (h) and TAP1 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting TAP1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: TAP1 Antibody (D-11): sc-518133
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TAP1 Double Nickase Plasmid (h) | sc-405210-NIC | 20 µg | $410.00 | |||
TAP1 Double Nickase Plasmid (h2) | sc-405210-NIC-2 | 20 µg | $410.00 |
TAP1 (transporter associated with antigen processing 1) encodes an ATP-binding cassette (ABC) transporter that forms a heterodimer with TAP2 to translocate proteasome-derived peptides from the cytosol into the endoplasmic reticulum for loading onto MHC class I molecules. This process is central to antigen processing and presentation, linking interferon-stimulated signaling, immunoproteasome activity, and ER peptide-loading complex function to CD8+ T cell immune surveillance. Altered TAP1 expression or function is associated with impaired MHC I surface presentation and immune evasion phenotypes observed in multiple tumor contexts, and with primary immunodeficiency features in rare antigen-presentation defects. TAP1 is therefore frequently studied in pathways governing host–pathogen interactions, tumor immunology, and mechanisms regulating MHC I assembly and trafficking.
TAP1 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the TAP1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within TAP1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt TAP1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of TAP1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.